← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Pharmasset, Inc.
Tucker, GA
$2,460,171
Total funding
15
Grants
Funding over time
peak $195K · FY2005–06$200K$150K$100K$50K$0
'05
'06
Funding mix
By agency
NIH$2,460,171 · 15
By mechanism
R43$1,799,087 · 12
R01$384,232 · 1
R41$276,852 · 2
Investigators at Pharmasset, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
NOVEL BENZAMIDE RIBOSIDE ANALOGUES AS ANTICANCER AGENTS$249,998
R43 · FY2001 · CA
ANTI-POXVIRUS NUCLEOSIDES:SYNTHESIS AND EVALUATION$214,155
R43 · FY2002 · AI
2'-AND/OR 4'-C-MODIFIED NUCLEOSIDES AS ANTI-HCV AGENTS$194,954
R01 · FY2005 · DK
2'-AND/OR 4'-C-MODIFIED NUCLEOSIDES AS ANTI-HCV AGENTS$189,277
R01 · FY2004 · DK
Enhancement of 5-Fluorouracil Chemotherapeutic Efficacy$176,852
R41 · FY2002 · CA
DIOXOLANE NUCLEOSIDES AS ANTIVIRAL AGENTS$175,260
R43 · FY2003 · AI
Novel Class of Compounds for Treatment of HCV Infections$175,000
R43 · FY2003 · AI
Modified nucleosides for Hepatitis C Virus$162,200
R43 · FY2002 · AI
Antivirals against HBV$147,584
R43 · FY2001 · AI
RACIVIR FOR TREATMENT OF HEPATITIS B AND HIV INFECTIONS$142,000
R43 · FY2000 · AI
AZIDE TECHNOLOGY FOR DRUG DEVELOPMENT$132,879
R43 · FY2001 · AI
NOVEL DIFFERENTIATION AGENTS AGAINST HUMAN LEUKEMIAS$100,010
R43 · FY2000 · CA
NOVEL COFACTOR ANALOGUES AS IMMUNOSUPPRESSANTS$100,001
R43 · FY2000 · AI
Design of EBVTK substrates to eradicate EBV+ tumors$100,000
R41 · FY2001 · CA
L-NUCLEOSIDES AS ANTI-HBV AGENTS$100,000
R43 · FY2000 · AI
Novel agents against West Nile Virus infections$100,000
R43 · FY2003 · AI
2'-AND/OR 4'-C-MODIFIED NUCLEOSIDES AS ANTI-HCV AGENTS$1
R01 · FY2006 · DK